Edwards Lifesciences Announces Corvia and Mitralign Strategic Investments
Edwards Lifesciences ($EW) today announced two strategic transactions to beef up their structural heart disease technologies.
The first transaction is a $35 million investment in Corviva Medical, which gives Edwards the exclusive right to acquire Corviva, the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction.
Corviva's InterAtrial Shunt Device is designed to provide continuous and dynamic decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure. The therapy currently has CE Mark in Europe, and is being studied as part of a FDA pivotal clinical trial.
Learn about Corvia
The second deal is for the acquisition of certain assets from Mitralign, Inc., which includes intellectual property and associated clinical and regulatory experience.
Mitralign is developing an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation.
Learn about the Mitralign Procedure
These investments are not expected to impact Edwards' 2019 financial guidance.